Organovo’s exVive3D Liver bioprinted human tissue models are created using proprietary 3D bioprinting technology. The resulting tissues contain precise and reproducible architecture that can remain fully functional and stable for greater than 40 days. exVive3D Liver models will be initially be made available through Organovo’s preclinical in vitro testing to provide predictive liver tissue-specific toxicity marker assessment as a supplement to in vitro and preclinical (non-GLP) animal testing.
- Precise and reproducible architecture
- Fully functional and stable for >40 days
- Predictive liver tissue-specific toxicity marker assessment
Figure 1: Sustained production of key liver metabolites over time in exVive3D Liver Bioprinted Human Tissue.
Figure 2: Demonstrated maintenance of tissue viability as measured by ATP levels over time in exVive3D Liver Bioprinted Human Tissue.
Figure 3: CYP3A4 induction and metabolic activity are sustained in exVive3D Liver Bioprinted Human Tissue.
Figure 4: Histologic structure in exVive3D Liver Bioprinted Human Liver Tissue Left: Primary hepatocytes demonstrating tissue-like cellular density (H&E); Center: Retention of desmin positive stellates and formation of endothelial cell networks (Desmin, CD31); Right: Formation of hepatocyte cell junctions (Albumin, E-Cadherin).
Figure 5; Left: Perfomance of 3D liver tissues measuring albumin production up to 42 days.; Right: Induction of CYP3A4 at moderate doses of diclofenac, followed by damage at higher doses as measured by lactate dehydrogenase (LDH).
Figure 6: H&E stained native human liver tissue exhibiting APAP toxicity (left); exVive3D Liver bioprinted human tissue treated with increasing doses of APAP (right)